Deficits in intracellular trafficking are a newly emerging, unifying theme in a broad range of neurological disorders, including Alzheimers Disease, Huntington's Disease, Parkinsons Disease and many others. Specific treatments for these disorders are either limited or unavailable. The meeting will look at how these trafficking deficits produce neuropathology, why these disorders are limited to the nervous system and how to elucidate trafficking networks and control points to identify novel drug targets. Specifically, it aims to: 1) Advance state-of-the-art knowledge in the cell biology of intracellular trafficking, the genetics of trafficking disorders, the clinical neurology of trafficking disorders and the methods used to identify drug targets;): Facilitate interactions between stakeholder groups who have traditionally had only limited contact; 3) Identify common themes, novel approaches and new collaborations to address the many large gaps in knowledge about trafficking disorders. For the first time, the meeting will bring together groups that have traditionally not interacted, including cell biologists who study trafficking but have predominantly studied non-neural cells, clinical neurologists who do not typically work in cell biology, geneticists who have discovered causative genes for a wide range of neurological disorders but typically have limited expertise in the biological function of the gene products they identify, and drug developers, to cross-fertilize ideas and generate new collaborations.